Objectives: This study aimed to examine the effect of long-term treatment with ritonavir-boosted atazanavir (atazanavir/ritonavir) on cholelithiasis.
Introduction
Ritonavir-boosted atazanavir (atazanavir/ritonavir) is a widely used protease inhibitor in the treatment of patients infected with HIV-1.
1 -3 Cholelithiasis was not reported in atazanavir/ ritonavir Phase 3 clinical trials; 4 however, recent post-marketing studies have suggested potential association between cumulative atazanavir/ritonavir exposure and cholelithiasis. 5 -7 Only a couple of studies have so far reported the incidence of complicated cholelithiasis, such as cholecystitis, cholangitis and pancreatitis, in patients treated with atazanavir/ritonavir. 5, 8 However, the effects of prolonged exposure to atazanavir/ritonavir on the incidence of cholelithiasis, including asymptomatic cholelithiasis, is unknown at this stage. This is of importance because 20% of patients with cholelithiasis develop symptoms in the long term.
population was HIV-1-infected patients, aged .17 years, who underwent abdominal ultrasonography at the Physiological Examination Unit of the hospital between 1 January 2004 and 31 March 2013 as part of clinical practice. Atazanavir/ritonavir became available in Japan in January 2004. Exclusion criteria were: (i) patients with cholecystectomy performed before the study period; and (ii) patients with missing data on antiretroviral therapy (ART). At the Physiological Examination Unit, ultrasonography was conducted by certified medical technologists and the images and diagnosis were double-checked and confirmed by radiologists, hepatologists or gastroenterologists. If abdominal ultrasonography was conducted more than once during the study period, the latest ultrasonography data were used for the study. This study was approved by the Human Research Ethics Committee of the hospital. Each participant provided a written informed consent for the clinical and laboratory data to be used and published for research purposes.
Measurements
The primary exposure variable was a history of atazanavir/ritonavir use for .2 years, regardless of continuation of atazanavir/ritonavir at the time of abdominal ultrasonography. A 2 years threshold for atazanavir/ritonavir exposure was selected because cholelithiasis was not reported in atazanavir/ritonavir Phase 3 clinical trials with the primary endpoint set at week 48 4 and prolonged excretion of atazanavir in the bile appears necessary for gallstone formation. 5 The potential risk factors for cholelithiasis were collected from the medical records, together with the basic demographics.
9,11 -13 They included age, sex, ethnicity, body mass index (BMI), cirrhosis, diabetes mellitus, CD4 count, HIV viral load, ART experienced or naive, duration of ART, length of exposure to atazanavir/ritonavir, ritonavirboosted lopinavir (lopinavir/ritonavir) and ritonavir-boosted darunavir (darunavir/ritonavir), history of AIDS and hepatitis B or C coinfection. We used data collected within 3 months of the day ultrasonography was conducted.
Statistical analysis
Univariate and multivariate logistic regression analysis was used to estimate the effects of atazanavir/ritonavir exposure of .2 years, relative to ,2 years or no atazanavir/ritonavir exposure, on cholelithiasis as the primary exposure. Basic demographics (age and sex), possible risk factors for cholelithiasis (BMI, cirrhosis and diabetes mellitus) 11 -13 and variables with P values ,0.05 in univariate analysis (HIV load and duration of ART) were added to the multivariate model. The variable 'treatment naive' was not added because of its multicollinearity with HIV load.
Statistical significance was defined as two-sided P values ,0.05. We used ORs and 95% CIs to estimate the effects of each variable on cholelithiasis. All statistical analyses were performed with the Statistical Package for Social Sciences ver. 20.0 (SPSS, Chicago, IL, USA).
Results
Of the 890 study patients, cholelithiasis was diagnosed by abdominal ultrasonography in 87 patients, with a prevalence of 9.8% (see Figure S1 , available as Supplementary data at JAC Online). Patients with cholelithiasis were significantly older, more likely to be females, have lower HIV-1 viral load, be diabetic, have cirrhosis and have longer exposure to ART (Table 1) . On the other hand, patients without cholelithiasis were more likely to be treatment naive.
Of the 890 study patients, 186 (21%) were treated with atazanavir for a median duration of 1.79 years (IQR 0.68 -3.78 years) and 84 (9.4%) patients were treated with atazanavir for .2 years. Of the 186 patients treated with atazanavir, 173 (93%) patients were on atazanavir/ritonavir, whereas only 13 (7%) were on non-boosted atazanavir. Cholelithiasis was twice as frequent in patients treated for .2 years with atazanavir [15 (18%) of 
Discussion
To our knowledge, this is the first study to investigate the effects of atazanavir/ritonavir exposure on cholelithiasis, including asymptomatic cholelithiasis. Patients treated for .2 years with atazanavir/ritonavir were twice as likely to develop cholelithiasis compared with patients with no or ,2 years of atazanavir/ritonavir exposure. Univariate analysis demonstrated a significant association between .2 years of atazanavir/ritonavir exposure and cholelithiasis (OR ¼ 2.216; 95% CI ¼ 1.206 -4.073; P ¼ 0.010) and the association almost persisted in multivariate analysis (adjusted OR ¼ 1.806; 95% CI ¼ 0.922 -3.537; P ¼ 0.085) ( Table 2) . Thus, long-term treatment with atazanavir/ritonavir was associated with cholelithiasis in this cohort. On the other hand, exposure to lopinavir/ritonavir or darunavir/ritonavir, other widely prescribed protease inhibitors, was not associated with cholelithiasis.
Two mechanisms are suggested for the observed atazanavirinduced cholelithiasis. First, precipitation of atazanavir in the bile might enhance the formation of calculi composed of atazanavir and other biliary components. This hypothesis is supported by the documentation of atazanavir as a component of gallstones in several case reports. 5 -7 Strong acidity (e.g. pH of 1.9) is required to achieve optimal dissolution of atazanavir, whereas biliary pH is usually .6.5. 4 This feature of atazanavir might result in precipitation of atazanavir and consequent cholelithiasis. 4 It is well known that atazanavir/ritonavir is a risk factor for nephrolithiasis 14, 15 and, recently, a case of atazanavir-containing sialolithiasis in a patient treated with atazanavir/ritonavir was also reported. 16 These data further support the likelihood of atazanavir involvement in lithiasis. Second, because atazanavir is a competitive 17 This might result in a rise in the bilirubin level in the bile, which could facilitate the formation of gallstones because bilirubin is also a component of such stones. This hypothesis is supported by a case report that showed the presence of indinavir, another protease inhibitor, in the gallstones of a patient on indinavir-containing ART. 18 Indinavir has similar characteristics to atazanavir: optimal solubility at low pH and being an inhibitor of UGT1A1. 18, 19 There are several limitations to our study. First, because stone composition analysis was not conducted in this study, one cannot rule out other causes of cholelithiasis in addition to atazanavir/ ritonavir. Second, the prevalence of gallstones is generally lower in Asians than in Europeans and since most of the patients in this study were Asian, the effect of atazanavir/ritonavir might be different in other populations. 20 Third, because the study population included patients who had undergone abdominal ultrasonography in clinical practice with various indications, the prevalence of cholelithiasis might be overestimated.
In conclusion, the present study demonstrated that patients on long-term treatment (.2 years) with atazanavir/ritonavir were twice as likely to develop cholelithiasis compared with those treated for ,2 years. A similar effect was not demonstrated in patients treated with lopinavir/ritonavir or darunavir/ritonavir. Long-term, large prospective studies are warranted to elucidate the incidence and risk factors for complicated cholelithiasis in patients exposed to atazanavir/ritonavir-containing ART.
